Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Lucía Sánchez-Peña *Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0007-5696-5812
Salud Rodríguez-Pallares *Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-8270-0259
Pablo Aja-MacayaServicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0001-6296-5949
Tania Blanco-MartínServicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0003-1636-6429
Lucía González-PintoServicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-8387-3784
Gloria Pérez-RodríguezServicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0002-8039-6641
Christophe Le TerrierMedical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0002-5455-5576
Inés Portillo-CalderónCIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-1692-9538
Esther RecachaCIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-7555-2924
Cristina RiazzoUnidad de Microbiología, Hospital Universitario Reina Sofía e Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.ORCID 0000-0001-9142-1617
Juan Carlos Vázquez-UchaServicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0003-4949-0779
Alejandro BeceiroServicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-6340-7815
Belén AracilCIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-6156-8252
Jesús Oteo-IglesiasCIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Luis Martínez-MartínezCIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Laurent PoirelMedical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0001-5160-5286
Germán Bou *Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0001-8837-0062
Jorge Arca-Suárez *Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-4248-503X
Funding
Axencia Galega de Innovación IN606A 2024/022Axencia Galega de Innovación IN607A 2024/09Axencia Galega de Innovación IN607D 2024/08Instituto de Salud Carlos III CB21/13/00049Instituto de Salud Carlos III CB21/13/00055Instituto de Salud Carlos III CB21/13/00095Instituto de Salud Carlos III CM23/00095Instituto de Salud Carlos III CM23/00104Instituto de Salud Carlos III FI23/00074Instituto de Salud Carlos III JR21/00026Instituto de Salud Carlos III PI20/01212Instituto de Salud Carlos III PI20/01749Instituto de Salud Carlos III PI21/00704Instituto de Salud Carlos III PI22/01212Instituto de Salud Carlos III PI23/00851
6 · The paper itself
Abstract
Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. · full record | OpenQuestion